RESUMO
PURPOSE: Patients with Graves' orbitopathy can present with asymmetric disease. The aim of this study was to identify clinical characteristics that distinguish asymmetric from unilateral and symmetric Graves' orbitopathy. METHODS: This was a multi-centre study of new referrals to 13 European Group on Graves' Orbitopathy (EUGOGO) tertiary centres. New patients presenting over a 4 month period with a diagnosis of Graves' orbitopathy were included. Patient demographics were collected and a clinical examination was performed based on a previously published protocol. Patients were categorized as having asymmetric, symmetric, and unilateral Graves' orbitopathy. The distribution of clinical characteristics among the three groups was documented. RESULTS: The asymmetric group (n = 83), was older than the symmetric (n = 157) group [mean age 50.9 years (SD 13.9) vs 45.8 (SD 13.5), p = 0.019], had a lower female to male ratio than the symmetric and unilateral (n = 29) groups (1.6 vs 5.0 vs 8.7, p < 0.001), had more active disease than the symmetric and unilateral groups [mean linical Activity Score 3.0 (SD 1.6) vs 1.7 (SD 1.7), p < 0.001 vs 1.3 (SD 1.4), p < 0.001] and significantly more severe disease than the symmetric and unilateral groups, as measured by the Total Eye Score [mean 8.8 (SD 6.6) vs 5.3 (SD 4.4), p < 0.001, vs 2.7 (SD 2.1), p < 0.001]. CONCLUSION: Older age, lower female to male ratio, more severe, and more active disease cluster around asymmetric Graves' orbitopathy. Asymmetry appears to be a marker of more severe and more active disease than other presentations. This simple clinical parameter present at first presentation to tertiary centres may be valuable to clinicians who manage such patients.
Assuntos
Oftalmopatia de Graves/diagnóstico , Oftalmopatia de Graves/patologia , Adulto , Idoso , Estudos Transversais , Progressão da Doença , Assimetria Facial/diagnóstico , Assimetria Facial/etiologia , Feminino , Oftalmopatia de Graves/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Prospectivos , Índice de Gravidade de DoençaRESUMO
PURPOSE: Intravenous glucocorticoids (ivGCs) given as 12-weekly infusions are the first-line treatment for moderate-to-severe and active Graves' orbitopathy (GO), but they are not always effective. In this study, we evaluated whether response at 6 weeks correlated with outcomes at 12 (end of intervention) and 24 (follow-up) weeks, particularly in patients initially unresponsive. METHODS: Our database (Bartalena et al. J Clin Endocrinol Metab 97:4454-4463, 10), comprising 159 patients given three different cumulative doses of methylprednisolone (2.25, 4.98, 7.47 g) was analyzed, pooling data for analyses. Responses at 6 weeks were compared with those at 12 and 24 weeks using three outcomes: overall ophthalmic involvement [composite index (CI)]; quality of life (QoL); Clinical Activity Score (CAS). Responses were classified as "Improved", "Unchanged", "Deteriorated", compared to baseline. RESULTS: Deteriorated patients at 6 weeks for CI (n = 8) remained in the same category at 12 weeks and 7/8 at 24 weeks. Improved patients at 6 weeks for CI (n = 51) remained in the same category in 63% and 53% of cases at 12 and 24 weeks, respectively. Unchanged patients at 6 weeks (n = 100) eventually improved in 28% of cases (CI), 58% (CAS), 32% (QoL). There was no glucocorticoid dose-dependent difference in the influence of early response on later outcomes. CONCLUSIONS: Patients who deteriorate at 6 weeks after ivGCs are unlikely to benefit from continuing ivGCs. Patients unresponsive at 6 weeks still have a significant possibility of improvement later. Accordingly, they may continue ivGC treatment, or, alternatively, possibly stop ivGCs and be switched to a second-line treatment.
Assuntos
Glucocorticoides/administração & dosagem , Oftalmopatia de Graves/tratamento farmacológico , Qualidade de Vida , Índice de Gravidade de Doença , Administração Intravenosa , Seguimentos , Humanos , Resultado do TratamentoRESUMO
BACKGROUND: Moyamoya disease (MMD) may be graded based on DSA, the presence of ischemia in MRI and cerebrovascular reserve capacity allowing the prediction of ischemic symptoms in patients. Cerebral ischemia represents a severe complication in revascularization surgery. Focusing on different clinical features of hemodynamic impairment, MMD grading may allow prediction of ischemic complications. It was the aim to analyze whether MMD grading stratifies for ischemic complications in revascularization surgery for MMD. METHOD: In 37 MMD patients a bilateral, standardized, one-staged revascularization approach consisting of STA-MCA bypass/encephalomyosynangiosis (EMS) and single EMS on the contralateral hemisphere was performed. Clinical data including DSA, MRI and rCBF (Xenon-CT) studies were assessed and used for grading MMD. All patients were observed on the ICU for at least 24 h and received CT imaging on the first postoperative day and in case of neurological deterioration. Ischemic complications were analyzed until the day of discharge and at 6-month follow-up. RESULTS: Grading of MMD revealed 11 hemispheres (15 %) as grade I, 33 hemispheres (44 %) as grade II and 30 hemispheres (41 %) as grade III. Eight ischemic complications were observed (11 %). MMD grading demonstrated a significant correlation with ischemic complications: 0 complications in grade I, 3 in grade II (9 %) and 5 in grade III hemispheres (16 %; p < 0.05, Fisher's exact test). CONCLUSIONS: The proposed grading system allows to stratify for ischemic complications in MMD patients that receive bilateral, one-staged revascularization surgery. Future studies will have to investigate its use for predicting ischemic complications in other revascularization strategies for MMD.
Assuntos
Isquemia Encefálica/etiologia , Revascularização Cerebral/efeitos adversos , Doença de Moyamoya/cirurgia , Complicações Pós-Operatórias/etiologia , Adulto , Isquemia Encefálica/diagnóstico por imagem , Angiografia Cerebral , Revascularização Cerebral/métodos , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Doença de Moyamoya/diagnóstico por imagem , Complicações Pós-Operatórias/diagnóstico por imagemRESUMO
Left temporal arachnoid cyst and specific learning disorders associated with pervasive developmental disorders - not otherwise specified (PDD-NOS): contributions of an integrative neuro-psychomotor, neuropsychological, psychopathological and neurosurgical approach about a case report in a child (François). With DSM-IV and DSM-IV-TR, the terminology of pervasive developmental disorders (PDD) covers two main categories of infantile disorders: disorders of "strictly" autistic nature and pervasive developmental disorders - not otherwise specified (PDD-NOS). Under the terminology of multiple complex developmental disorder (MCDD), it is proposed to classify children presenting symptoms approaching the psychotic disharmonies and usually diagnosed as PDD-NOS. Such a category of developmental disorders is now included without nosographic distinction in the autistic spectrum in the Diagnostic and Statistical Manual of mental disorders (DSM-V). CASE REPORT: We are reporting a case report of a 6-year-old boy which shows a PDD-NoS/MCDD complex symptomatology type. This child presents multiple disorders: minor neurological signs (soft signs), neuro-psychomotor disorders, developmental coordination disorder (DCD), communication, thought, and regulation of emotions disorders, attention deficit disorders (ADD); in the presence of a high verbal intellectual potential, which makes it difficult to establish a clear diagnosis. A cerebral magnetic resonance imaging (MRI) was carried out due to the presence of minor neurological signs (soft signs) and of neurodevelopmental multiple disorders. The MRI revealed a voluminous arachnoid temporo-polar left cyst with a marked mass effect on the left temporal lobe. DISCUSSION: A neurosurgical intervention allowed to observe the gradual disappearance of the specific symptomatology (in particular soft signs, neuro-psychomotor functions and autistic symptoms) secondary to the interference of the cyst's pressure with intracranial areas involving neurological and psychopathological abnormalities, underlying at the same time the reversibility of the disorders after decompression as demonstrated in some studies. There are always, with a quantitative and qualitative decrease, an emotional dysregulation, a DCD, an ADD as well as impairments in the executive functions. CONCLUSION: This clinical case underlines the necessity of an evaluation in a transdisciplinary way and to follow the developmental evolution of the child in order to focus adapted therapeutics. Furthermore, with neurodevelopmental disorders not specified, it is important to examine the presence of soft signs with standardized neuro-psychomotor assessment, and then, to propose an MRI investigation. To our knowledge, this is the first report in the literature with a school age child of an unusual association between a temporal arachnoid cyst associated with PDD-NOS/MCDD.
Assuntos
Cistos Aracnóideos/terapia , Transtornos Globais do Desenvolvimento Infantil/terapia , Procedimentos Neurocirúrgicos/métodos , Transtorno de Aprendizagem Específico/terapia , Lobo Temporal/cirurgia , Cistos Aracnóideos/psicologia , Cistos Aracnóideos/cirurgia , Transtorno do Deficit de Atenção com Hiperatividade/etiologia , Transtorno Autístico/etiologia , Transtorno Autístico/terapia , Criança , Transtornos Globais do Desenvolvimento Infantil/psicologia , Transtornos Globais do Desenvolvimento Infantil/cirurgia , Terapia Combinada , Humanos , Imageamento por Ressonância Magnética , Masculino , Transtornos das Habilidades Motoras/etiologia , Escalas de Graduação Psiquiátrica , Transtornos Psicomotores/etiologia , Transtornos Psicomotores/terapia , Transtorno de Aprendizagem Específico/psicologia , Transtorno de Aprendizagem Específico/cirurgia , Resultado do TratamentoRESUMO
We describe a patient who had four relapses of Miller Fisher syndrome over a period of 20 years. The classical triad - ophthalmoparesis, ataxia and areflexia - was present during the first two attacks; ataxia was not observed during the third episode. The final recurrence was characterized by signs suggestive of a central involvement of the oculomotor pathways, subclinical slowing of the visual-evoked potentials, and peripheral vestibular hyporeactivity. Brain imaging was normal, but high levels of anti-GQ1b IgG antibodies were detectable during the second relapse and persisted after the fourth recurrence despite complete clinical recovery.
Assuntos
Síndrome de Miller Fisher/complicações , Doenças Vestibulares/etiologia , Adolescente , Testes Calóricos , Lateralidade Funcional , Humanos , Masculino , Movimentos Sacádicos , Vestíbulo do Labirinto/fisiopatologiaRESUMO
PURPOSE: To assess the predictive value for functional recovery of Ganglion Cell Complex Layer (GCC) and Retinal Nerve Fiber Layer (RNFL) measurements obtained by Optical Coherence Tomography (OCT) in patients undergoing chiasmal decompression and to define potential OCT thresholds for visual recovery. METHODS: We measured preoperative GCC and RNFL thickness in patients with a sellar and/or perisellar tumor compressing the optic chiasm. Visual recovery was defined as recovery of mean deviation (MD) and pattern standard deviation (PSD) using Humphrey visual field testing after 12 successful decompressions (24 eyes). Receiver operating characteristic curve (ROC) analysis was used to identify the best thresholds. RESULTS: Robust global and focal OCT thresholds were found. Superior GCC≥63µm had the best functional prognostic value (AUC=1) for visual improvement. Mean GCC ≥ 67µm and mean RNFL≥75µm also had excellent predictive values (AUC>0.9). CONCLUSION: In this preliminary study, significant preoperative OCT thresholds for early visual recovery after chiasmal decompression were identified, mainly regarding GCC measurements. Further studies on larger cohorts with closely scheduled follow-up could refine our results.
Assuntos
Quiasma Óptico , Tomografia de Coerência Óptica , Descompressão , Humanos , Fibras Nervosas , Quiasma Óptico/diagnóstico por imagem , Prognóstico , Curva ROC , Células Ganglionares da Retina , Campos VisuaisRESUMO
Evaluation of the radioisotopic purity of technetium-99m (99mTc) produced in GBq amounts by proton bombardment of enriched molibdenum-100 (100Mo) metallic targets at low proton energies (i.e. within 15-20 MeV) is conducted. This energy range was chosen since it is easily achievable by many conventional medical cyclotrons already available in the nuclear medicine departments of hospitals. The main motivation for such a study is in the framework of the research activities at the international level that have been conducted over the last few years to develop alternative production routes for the most widespread radioisotope used in medical imaging. The analysis of technetium isotopes and isomeric states (9xTc) present in the pertechnetate saline Na99mTcO4 solutions, obtained after the extraction/purification procedure, reveals radionuclidic purity levels basically in compliance with the limits recently issued by European Pharmacopoeia 9.3 (2018 Sodium pertechnetate (99mTc) injection 4801-3). Moreover, the impact of 9xTc contaminant nuclides on the final image quality is thoroughly evaluated, analyzing the emitted high-energy gamma rays and their influence on the image quality. The spatial resolution of images from cyclotron-produced 99mTc acquired with a mini-gamma camera was determined and compared with that obtained using technetium-99m solutions eluted from standard 99Mo/99mTc generators. The effect of the increased image background contribution due to Compton-scattered higher-energy gamma rays (E γ > 200 keV), which could cause image-contrast deterioration, was also studied. It is concluded that, due to the high radionuclidic purity of cyclotron-produced 99mTc using 100Mo(p,2n)99mTc reaction at a proton beam energy in the range 15.7-19.4 MeV, the resulting image properties are well comparable with those from the generator-eluted 99mTc.
Assuntos
Compostos Radiofarmacêuticos/normas , Tecnécio/normas , Ciclotrons , Isótopos/química , Molibdênio/química , Prótons , Compostos Radiofarmacêuticos/química , Pertecnetato Tc 99m de Sódio/química , Tecnécio/químicaRESUMO
BACKGROUND: Graves' orbitopathy (GO) is an autoimmune condition, which is associated with poor clinical outcomes including impaired quality of life and socio-economic status. Current evidence suggests that the incidence of GO in Europe may be declining, however data on the prevalence of this disease are sparse. Several clinical variants of GO exist, including euthyroid GO, recently listed as a rare disease in Europe (ORPHA466682). The objective was to estimate the prevalence of GO and its clinical variants in Europe, based on available literature, and to consider whether they may potentially qualify as rare. Recent published data on the incidence of GO and Graves' hyperthyroidism in Europe were used to estimate the prevalence of GO. The position statement was developed by a series of reviews of drafts and electronic discussions by members of the European Group on Graves' Orbitopathy. The prevalence of GO in Europe is about 10/10,000 persons. The prevalence of other clinical variants is also low: hypothyroid GO 0.02-1.10/10,000; GO associated with dermopathy 0.15/10,000; GO associated with acropachy 0.03/10,000; asymmetrical GO 1.00-5.00/10,000; unilateral GO 0.50-1.50/10,000. CONCLUSION: GO has a prevalence that is clearly above the threshold for rarity in Europe. However, each of its clinical variants have a low prevalence and could potentially qualify for being considered as a rare condition, providing that future research establishes that they have a distinct pathophysiology. EUGOGO considers this area of academic activity a priority.
Assuntos
Doenças Raras/diagnóstico , Doenças Raras/epidemiologia , Europa (Continente) , Oftalmopatia de Graves/diagnóstico , Oftalmopatia de Graves/epidemiologia , Oftalmopatia de Graves/metabolismo , Humanos , Guias de Prática Clínica como Assunto , Qualidade de Vida , Doenças Raras/metabolismoRESUMO
Transient neuroimaging features indicating primary cortical and secondary subcortical white matter cytotoxic oedema have been described in association with prolonged or intense seizures. We describe the unusual condition of recurrent ictal cortical blindness due to focal occipital status epilepticus, in the context of chronic hepatic failure. There was a close association between the onset and disappearance of clinical, electrophysiological and magnetic resonance imaging abnormalities.
Assuntos
Cegueira Cortical/etiologia , Encefalopatia Hepática/complicações , Falência Hepática/complicações , Estado Epiléptico/complicações , Anticonvulsivantes/uso terapêutico , Cegueira Cortical/tratamento farmacológico , Cegueira Cortical/fisiopatologia , Edema Encefálico/tratamento farmacológico , Edema Encefálico/etiologia , Edema Encefálico/fisiopatologia , Doença Crônica , Eletroencefalografia , Evolução Fatal , Feminino , Encefalopatia Hepática/fisiopatologia , Humanos , Imageamento por Ressonância Magnética , Pessoa de Meia-Idade , Recidiva , Estado Epiléptico/tratamento farmacológico , Estado Epiléptico/fisiopatologia , Córtex Visual/efeitos dos fármacos , Córtex Visual/fisiopatologiaRESUMO
BACKGROUND/AIM: Thyroid associated orbitopathy (TAO) and Graves' disease (GD) have an autoimmune pathogenesis, possibly related to the thyrotropin receptor (TSHR). The aim of this study was to determine whether TSHR immunoreactivity is correlated with disease severity or serum TSHR antibody (TRAB) levels. METHODS: Orbital tissues from 30 patients with TAO were compared with those of 20 patients with strabismus and four with non-thyroid orbital inflammation. TSHR was detected by immunohistochemistry and TRAB were measured by radioreceptor assay. RESULTS: No TSHR immunoreactivity was detected in the 24 control orbital tissues, whereas in all TAO biopsies elongated fibroblast-like cells, expressing TSHR, were present. These cells were located between the muscle cells, which were separated by oedema in the acute phase but fibrous tissue in the chronic phase of disease. Semi-thin sections showed numerous mast cells present in the chronic phase and in close contact with adipocytes. The number of TSHR immunostained cells was high in early disease, decreased with disease duration, and was positively correlated with TRAB levels at the onset of TAO. CONCLUSION: TSHR immunoreactivity was demonstrated specifically in TAO orbits which highlights the importance of TRAB early in the pathogenesis.
Assuntos
Doenças Autoimunes/metabolismo , Doença de Graves/metabolismo , Músculos Oculomotores/metabolismo , Doenças Orbitárias/metabolismo , Receptores da Tireotropina/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Autoanticorpos/sangue , Doenças Autoimunes/imunologia , Doenças Autoimunes/patologia , Biópsia , Progressão da Doença , Feminino , Doença de Graves/imunologia , Doença de Graves/patologia , Humanos , Técnicas Imunoenzimáticas , Masculino , Pessoa de Meia-Idade , Músculos Oculomotores/patologia , Órbita/metabolismo , Órbita/patologia , Doenças Orbitárias/imunologia , Receptores da Tireotropina/imunologia , Índice de Gravidade de Doença , Tireoidite Autoimune/imunologia , Tireoidite Autoimune/metabolismo , Tireoidite Autoimune/patologiaAssuntos
Erros de Diagnóstico , Esclerose Múltipla/diagnóstico , Neurite Óptica/diagnóstico , Síndrome de Susac/diagnóstico , Adulto , Diagnóstico Tardio , Diagnóstico Diferencial , Feminino , Humanos , Imageamento por Ressonância Magnética , Esclerose Múltipla/complicações , Neurite Óptica/complicações , Tomografia de Coerência Óptica , Testes de Campo VisualRESUMO
Recently, great attention has been paid to calcium phosphate cements, because of their advantages in comparison with conventional calcium phosphate bioceramics employed for bone repairing, regarding in situ handling, and shaping abilities. Nevertheless, the calcium phosphate cements exhibit relatively low mechanical strength. The aim of this work was the improvement of the compressive strength of alpha-tricalcium phosphate-based cement. The hydraulic setting reaction of this system produces a calcium-deficient hydroxyapatite phase suitable for bone repairing: alpha-Ca3(PO4)2 + H2O --> Ca9(HPO4)(PO4)5OH. Mechanical strength can be improved using technological solutions developed for other applications, such as Portland cement and dual-setting glass-ionomers, by using polymeric additives. The additives used in this work were sodium alginate, sodium polyacrylate, and an in situ polymerization system resulting in a polyacrylamide crosslinked hydrogel. Parameters evaluated were setting time, compressive strength before and after immersion in simulated body fluid, density, porosity, crystalline phases, and microstructure. Sodium alginate and sodium polyacrylate were deleterious to both setting time and mechanical strength. When the in situ polymerization system was added, two setting reactions progressed in parallel: the conventional hydraulic reaction and the copolymerization of acrylamide and crosslinking water-soluble monomers. The initial and final setting times of the "dual-setting" cement were 9 and 35 min, respectively, and they can be regulated varying the initiator, catalyst, and monomers concentrations. The initial compressive strength of the dual-setting cement (6.8 MPa at 0 h, and 15.2 MPa at 24 h) is higher than that of unmodified cement. The major crystalline phase after setting is hydroxyapatite. The dual-setting cement seems to be suitable for clinical applications in bone repairing and remodeling.
Assuntos
Cimentos Ósseos/química , Substitutos Ósseos/química , Fosfatos de Cálcio/química , Resinas Acrílicas/química , Alginatos/química , Líquidos Corporais/química , Força Compressiva , Reagentes de Ligações Cruzadas/química , Ácido Glucurônico , Ácidos Hexurônicos , Teste de Materiais , Microscopia Eletrônica de Varredura , Polímeros/química , Porosidade , Propriedades de Superfície , Difração de Raios XRESUMO
Calcium phosphate-based bioceramics have revolutionized orthopedic and dental repair of damaged parts of the bone system. Among these materials, calcium phosphate-based cements, with hydraulic setting, stand out due to their biocompatibility and in situ hardening, which allow easy manipulation and adaptation to the shape and dimensions of bone defects. An investigation was made of the in vitro cytotoxic effect of calcium phosphate cement based on alpha-tricalcium phosphate, immersed for different lengths of time in simulated body fluid (SBF), based on the ISO-10993 "Biological Evaluation of Medical Devices" standard. The culture medium was Chinese hamster ovary (CHO) cells in contact with diluted cement extracts. The results revealed that the calcium phosphate cement used was cytotoxic and that the material's cytotoxicity decreased the longer the cement was immersed in SBF.
Assuntos
Materiais Biocompatíveis/farmacologia , Cimentos Ósseos/farmacologia , Fosfatos de Cálcio/química , Animais , Líquidos Corporais/química , Células CHO , Células Cultivadas , Cricetinae , Concentração de Íons de Hidrogênio , Concentração Inibidora 50 , Teste de Materiais , Microscopia Eletrônica de Varredura , Fatores de Tempo , Difração de Raios X , Raios XRESUMO
A new protein (SA-5K) secreted in culture filtrates by Mycobacterium bovis, Mycobacterium tuberculosis, and few other mycobacterial species was previously identified and purified in our laboratory. In order to evaluate the putative role of SA-5K during intracellular mycobacterial growth, in the present study the SA-5K gene was cloned and expressed in Mycobacterium smegmatis, a rapid growing non-pathogenic mycobacterium which does not contain the gene for the protein. SA-5K expression in the THP-1 human macrophage cell line infected with the recombinant strain (M. smegmatis-pROL5K) was demonstrated by RT-PCR on RNA extracted from bacterial cells following 24 and 48 h of infection. Intracellular SA5K expression was associated with a higher cfu increase of M. smegmatis-pROL5K in comparison to the negative control strain (M. smegmatis recombinant for the cloning vector) (P=0.01). No significant change in SA-5K synthesis by M. smegmatis-pROL5K was observed when the recombinant strain was grown in vitro in different stress conditions such as iron deprivation, pH 4.5, presence of nitric oxide or hydrogen peroxide. The results presented in this study suggest a possible role for SA-5K in intracellular survival of recombinant M. smegmatis, though the function of the protein remains unknown.
Assuntos
Antígenos de Bactérias/genética , Antígenos de Bactérias/metabolismo , Macrófagos/microbiologia , Mycobacterium smegmatis/crescimento & desenvolvimento , Mycobacterium smegmatis/genética , Mycobacterium tuberculosis/genética , Linhagem Celular , Meios de Cultura , Humanos , Infecções por Mycobacterium não Tuberculosas/microbiologia , Mycobacterium smegmatis/fisiologia , Mycobacterium tuberculosis/imunologia , Mycobacterium tuberculosis/metabolismo , Recombinação GenéticaRESUMO
The octapeptide D-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-NH(2) ([D-Ala(1)]TNH(2)), an analog of peptide T (H-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-OH) associated with CD(4)/T(4) receptors involved in human immunodeficiency virus infection, was combined with the chelating polyazamacrocycle 1,4,8,11-tetraazacyclotetradecane (cyclam) to afford the bifunctional ligand cyc-[D-Ala(1)]TNH(2). This was then reacted with [(99m)TcO(4)](-) and Sn(2+) to yield the monocationic complex [(99m)Tc(O)(2)(cyc-[D-Ala(1)]TNH(2))](+). Biological activity of both the cyclam-peptide conjugate and the resulting Tc-99m complex were evaluated by measuring their chemotactic indexes. Results showed that N-cyclam acylation and subsequent labeling with Tc-99m of [D-Ala(1)]TNH(2) were tolerated, and both cyc-[D-Ala(1)]TNH(2) and [(99m)Tc(O)(2)(cyc-[D-Ala(1)]TNH(2))](+) retained the high chemotactic capacity of the original octapeptide. Biodistribution of the Tc-99m complex was carried out in rats. Fast blood clearance and no accumulation in organs of interest were observed.
Assuntos
Antígenos CD4/metabolismo , Oligopeptídeos/síntese química , Oligopeptídeos/metabolismo , Compostos de Organotecnécio/síntese química , Compostos de Organotecnécio/metabolismo , Compostos Radiofarmacêuticos/síntese química , Compostos Radiofarmacêuticos/metabolismo , Animais , Quimiotaxia de Leucócito , Cromatografia Líquida de Alta Pressão , Cromatografia em Papel , Feminino , Humanos , Técnicas In Vitro , Ligantes , Monócitos/metabolismo , Oligopeptídeos/farmacocinética , Compostos de Organotecnécio/farmacocinética , Compostos Radiofarmacêuticos/farmacocinética , Ratos , Ratos Sprague-Dawley , Distribuição TecidualRESUMO
A new efficient approach for the preparation of (188)Re radiopharmaceuticals starting from [(188)ReO(4)](-), produced at a carrier-free level through the (188)W/(188)Re generator system, is described. The reaction procedure was based on the combined action of different reagents and has been applied in detail to the preparation of the therapeutic agent (188)Re(V)-DMSA (H(2)DMSA [meso-2,3-dimercaptosuccinic acid]). The most efficient combination required the use of SnCl(2), oxalate ions, and gamma-cyclodextrin. These were reacted with [(188)ReO(4)](-) and H(2)DMSA to afford the final radiopharmaceutical in high radiochemical purity, at room temperature, and in weakly acidic solution. The role played by the various reagents in the reaction was investigated. It was found that SnCl(2) behaved as the actual reducing agent, whereas oxalate and gamma-cyclodextrin greatly enhanced the ease of reduction of [(188)ReO(4)](-) through the action of two hypothetical mechanisms. In the first step of the reaction, oxalate ions gave rise to the formation of Re(VII) complexes with the concomitant expansion of the coordination sphere of the metal. This process strongly favored the electron transfer between Sn(2+) and Re(+7) centers, giving rise to intermediate reduced rhenium complexes. These species were further stabilized by the formation of transient host-guest aggregates with gamma-cyclodextrin and finally converted into (188)Re(V)-DMSA through simple replacement of the coordinated ligands by H(2)DMSA.
Assuntos
Compostos Organometálicos/síntese química , Compostos Radiofarmacêuticos/síntese química , Rênio/química , Succímero/síntese química , Ciclodextrinas/química , Estabilidade de Medicamentos , Oxirredução , Compostos de Estanho/químicaRESUMO
The synthesis, at tracer level, of two Tc-99m complexes having the same chemical composition and structure, but differing by one electron in the total electron counting, is reported. These compounds have been prepared by reacting [99mTcO4]- with the piperidinium salt of the ligand ferrocenedithiocarboxylate {[Fe(II)(C5H4CS2)(C5H5)]- = FcCS}, in the presence of N-methyl S-methyldithiocarbazate as donor of N3-groups, and triphenylphosphine or SnCl2 as reducing agents. The formation of the neutral complex [99mTc(N)(FcCS)2] (compound A) and of the monocationic, mixed-valence complex [99mTc(N)(FcCS) (FcCS)]+ (compound B) {FcCS = [Fe(III)(C5H4CS2)(C5H5)]} was obtained in high yield. Both complexes comprise a terminal Tc triple bond N multiple bond and two FcCS ligands coordinated to the metal center through the two sulfur atoms of the -CS2 group, but they differ in the oxidation state of one of the two iron atoms of the coordinated FcCS ligands. In complex A, the two Fe atoms are both in the +2 oxidation state, while in B, one Fe atom is in the +2 and the other is in the +3 oxidation state. Thus, B is a mixed-valence Fe(II)-Fe(III) complex. B is easily converted into A by one-electron exchange with various reductants such as triphenylphosphine and excess SnCl2. Biodistribution studies in rats showed that complexes A and B are mostly retained in lungs and liver without any significant uptake in organs such as heart and brain.
Assuntos
Compostos Ferrosos/síntese química , Compostos de Organotecnécio/síntese química , Compostos Radiofarmacêuticos/síntese química , Animais , Feminino , Compostos Ferrosos/sangue , Compostos Ferrosos/metabolismo , Humanos , Fígado/metabolismo , Pulmão/metabolismo , Compostos de Organotecnécio/sangue , Compostos de Organotecnécio/metabolismo , Oxirredução , Compostos Radiofarmacêuticos/sangue , Compostos Radiofarmacêuticos/metabolismo , Ratos , Ratos Sprague-Dawley , Distribuição TecidualRESUMO
A novel class of technetium-99m radiopharmaceuticals showing high heart uptake is described. These complexes were prepared through a simple and efficient procedure, and their molecular structure fully characterized. They are formed by a terminal Tc(triple bond)N multiple bond and two bidentate phosphine-thiol ligands [R(2)P-(CH(2))(n)SH, n=2,3] coordinated to the metal ion through the neutral phosphorus atom and the deprotonated thiol sulfur atom. The resulting geometry was trigonal bipyramidal. Biodistribution studies were carried out in rats. The complexes exhibited high initial heart uptake and elimination through liver and kidneys. The washout kinetic from heart was dependent on the nature of the lateral R groups on the phosphine-thiol ligands. When R=phenyl, heart activity was rapidly eliminated within 10-20 min. Instead, when R=tolyl, cyclohexyl, persistent heart uptake was observed. Extraction of activity from myocardium tissue showed that no change of the chemical identity of the tracer occurred after heart uptake. On the contrary, metabolization to more hydrophilic species occurred in liver and kidneys.
Assuntos
Compostos Radiofarmacêuticos/síntese química , Tecnécio , Animais , Feminino , Compostos Radiofarmacêuticos/isolamento & purificação , Compostos Radiofarmacêuticos/farmacocinética , Ratos , Ratos Sprague-Dawley , Distribuição TecidualRESUMO
Asymmetrical heterocomplexes containing a terminal technetium-nitrogen multiple bond coordinated to one diphosphine ligand (PNP) and one dithiocarbamate ligand (DBODC), were obtained through a simple two-step procedure under controlled conditions. The resulting complexes [99mTc(N)(PNP)(DBODC)]+ are monocationic, and possess a distorted square-pyramidal geometry where the Tc triple bond N multiple bond occupies an apical position and the diphosphine and dithiocarbamate ligands span the residual four coordination positions on the basal plane through the two phosphorus atoms and the two sulfur atoms, respectively. Biodistribution data in rats demonstrated that these complexes were rapidly extracted by the myocardium, and retained in this region for a prolonged time. After a few minutes post-injection, lung uptake became negligible, and liver washout was extremely rapid and quantitative. Analysis of heart/liver uptake ratios for these complexes revealed that their values increased exponentially in time, and after 60 min post-injection liver activity was almost completely eliminated into the intestine. Comparison with heart/liver ratios determined for 99mTc sestamibi and 99mTc tetrfosmin showed that values for these latter compounds were approximately 10 times lower than those measured for [99mTc(N)(PNP)(DBODC)]+ complexes at 60 min post-injection. In conclusion, the monocationic tracers [99mTc(N)(PNP)(DBODC)]+ exhibit high myocardial uptake in rats and dramatically high heart/lung and heart/liver ratios, suggesting that this novel class of perfusion agents could be conveniently employed to obtain heart images with superior imaging quality.